Dr. Reddy’s announces the Launch of Tacrolimus Capsules, the generic version of Prograf®
May 21, 2010, Hyderabad, India: Dr. Reddy’s Laboratories (NYSE: RDY) today announced that it has launched tacrolimus capsules, (0.5mg, 1mg, 5mg), a bioequivalent generic version of Prograf® Capsules*, in the US market on May 20, 2010. The United States Food & Drug Administration (USFDA) granted an approval of Dr. Reddy’s ANDA for tacrolimus capsules on May 13, 2010.
Tacrolimus is indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver, kidney, or heart transplants. Dosing should be titrated based on clinical assessments of rejection and tolerability. Dr. Reddy’s product is available in bottles of 100 count capsules.
The Prograf® brand and the tacrolimus generics had combined sales of approximately $955 million in the United States, based on IMS sales data for the 12 months ending March 31, 2010.
®Prograf is a registered trademark of Astellas Pharma US, Inc.
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.
About Dr. Reddy’s
Established in 1984, Dr. Reddy’s Laboratories (NYSE: RDY) is an emerging global pharmaceutical company. We
fulfill our purpose of providing affordable and innovative medicines through three core businesses:
Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Our products are marketed globally, with a focus on India, US, UK, Germany and Russia& CIS.
For more information please contact:
S Rajan at firstname.lastname@example.org / +91-40-66511725
Investors and Financial Analysts:
Kedar Upadhye at email@example.com / +91-40-66834297
Raghavender R at firstname.lastname@example.org / +91-40-66511529
Milan Kalawadia (USA) at email@example.com / +1 908-203-4931